三阴性乳腺癌中的肿瘤浸润淋巴细胞与铂类反应 - Suppr

Suppr

超能文献

Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer.

作者信息

Tung Nadine M, Winer Eric P

机构信息

Beth Israel Deaconess Medical Center, Boston, MA

Dana-Farber Cancer Institute, Boston, MA.

出版信息

J Clin Oncol. 2015 Mar 20;33(9):969-71. doi: 10.1200/JCO.2014.59.6031. Epub 2015 Jan 5.

DOI:10.1200/JCO.2014.59.6031

PMID:25559817

Abstract

摘要

相似文献

Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer.

J Clin Oncol. 2015 Mar 20;33(9):969-71. doi: 10.1200/JCO.2014.59.6031. Epub 2015 Jan 5.

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

J Clin Oncol. 2015 Mar 20;33(9):983-91. doi: 10.1200/JCO.2014.58.1967. Epub 2014 Dec 22.

Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy.

Breast Cancer Res Treat. 2019 Feb;174(1):1-13. doi: 10.1007/s10549-018-5066-6. Epub 2018 Nov 28.

Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy?

Surg Oncol Clin N Am. 2018 Jan;27(1):141-153. doi: 10.1016/j.soc.2017.08.004.

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.

Oncotarget. 2016 Oct 18;7(42):67686-67698. doi: 10.18632/oncotarget.11891.

A meta-analysis of platinum-based neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy for triple-negative breast cancer.

Future Oncol. 2019 Aug;15(23):2779-2790. doi: 10.2217/fon-2019-0165. Epub 2019 Jul 11.

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.

Lancet Oncol. 2018 Jan;19(1):40-50. doi: 10.1016/S1470-2045(17)30904-X. Epub 2017 Dec 7.

Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival.

J Chemother. 2016 Jun;28(3):210-7. doi: 10.1179/1973947815Y.0000000061. Epub 2016 May 27.

Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.

Breast. 2018 Aug;40:141-146. doi: 10.1016/j.breast.2018.05.007. Epub 2018 May 22.

Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer.

Clin Cancer Res. 2016 Dec 1;22(23):5747-5754. doi: 10.1158/1078-0432.CCR-15-2338. Epub 2016 May 17.

引用本文的文献

Doxorubicin-loaded NK exosomes enable cytotoxicity against triple-negative breast cancer spheroids.

Iran J Basic Med Sci. 2024;27(12):1604-1615. doi: 10.22038/ijbms.2024.79378.17194.

Pharmacological Inhibition of Necroptosis Promotes Human Breast Cancer Cell Proliferation and Metastasis.

Onco Targets Ther. 2020 Apr 16;13:3165-3176. doi: 10.2147/OTT.S246899. eCollection 2020.

Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy.

J Nanobiotechnology. 2019 Sep 3;17(1):93. doi: 10.1186/s12951-019-0526-7.

Platelet-to-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer.

PLoS One. 2018 Nov 14;13(11):e0207224. doi: 10.1371/journal.pone.0207224. eCollection 2018.

Distribution and prognostic value of tumor‑infiltrating T cells in breast cancer.

Mol Med Rep. 2018 Nov;18(5):4247-4258. doi: 10.3892/mmr.2018.9460. Epub 2018 Sep 5.

Role of Platinum in Early-Stage Triple-Negative Breast Cancer.

Curr Treat Options Oncol. 2017 Nov 6;18(11):68. doi: 10.1007/s11864-017-0506-9.

Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.

Cancer Biol Ther. 2017 Jun 3;18(6):369-378. doi: 10.1080/15384047.2017.1323582. Epub 2017 May 11.

Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.

PLoS Med. 2016 Dec 13;13(12):e1002193. doi: 10.1371/journal.pmed.1002193. eCollection 2016 Dec.

An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.

Breast Cancer Res. 2016 Dec 3;18(1):121. doi: 10.1186/s13058-016-0783-4.

A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.

Mol Oncol. 2016 Dec;10(10):1585-1594. doi: 10.1016/j.molonc.2016.09.007. Epub 2016 Oct 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验